Economic burden of COVID-19, China, January–March, 2020: a cost-of-illness study

Huajie Jin, Haiyin Wang, Xiao Li, Weiwei Zheng, Shanke Ye, Sheng Zhang, Jiahui Zhou & Mark Pennington

Objective To estimate the economic cost of coronavirus disease 19 (COVID-19) in 31 provincial-level administrative regions and in total, in China.

Methods We used data from government reports, clinical guidelines and other publications to estimate the main cost components of COVID-19 during 1 January–31 March 2020. These components were: identification and diagnosis of close contacts; suspected cases and confirmed cases of COVID-19; treatment of COVID-19 cases; compulsory quarantine of close contacts and suspected cases; and productivity losses for all affected residents. Primary outcomes were total health-care and societal costs.

Findings The total estimated health-care and societal costs associated with COVID-19 were 4.26 billion Chinese yuan (¥ 0.62 billion United States dollars, US$) and ¥ 2646.70 billion (US$ 383.02 billion), respectively. Inpatient care accounted for 44.2% (¥ 0.95 billion/¥ 2.15 billion) of routine health-care costs followed by medicines, accounting for 32.5% (¥ 0.70 billion/¥ 2.15 billion). Productivity losses accounted for 99.8% (¥ 2641.61 billion/¥ 2646.70 billion) of societal costs, which were mostly attributable to the effect of movement-restriction policies on people who did not have COVID-19. Societal costs were most sensitive to salary costs and number of working days lost due to movement-restriction policies. Hubei province had the highest health-care cost while Guangdong province had the highest societal cost.

Conclusion Our results highlight the high economic burden of the COVID-19 outbreak in China. The control measures to prevent the spread of disease resulted in substantial costs from productivity losses amounting to 2.7% (US$ 382.29 billion/US$ 14.14 trillion) of China’s annual gross domestic product.

Introduction

Coronavirus disease 2019 (COVID-19) is an infectious disease which results in substantial morbidity and mortality in some population groups. By September 2020, over 32.7 million cases of COVID-19 had been confirmed worldwide, of which 90.966 were in China. Prevention and treatment of COVID-19 can be expensive. According to Chinese clinical guidelines, all confirmed cases of COVID-19 should receive inpatient care. Moreover, patients with critical COVID-19 often require costly treatment such as mechanical ventilation and extracorporeal membrane oxygenation, potentially substantially increasing health-care costs. The societal cost of COVID-19 could be even greater. To prevent disease transmission, a series of emergency measures were implemented by the Chinese government, including isolation of COVID-19 cases, 14-day quarantine for close contacts of COVID-19 cases, lockdown of Wuhan city and adjacent areas, travel restrictions and extension of the Chinese New Year holiday period. While these containment strategies inevitably reduced the transmission of COVID-19, they inevitably caused a considerable loss in productivity.

This study assessed the health and societal costs of the COVID-19 outbreak in 31 provincial-level administrative regions in mainland China.

Methods

We conducted and reported our study according to the cost-of-illness checklist. 8

Study population

The population of interest was all residents in mainland China, which has 31 provincial-level administrative regions – 22 provinces, five autonomous regions (Guangxi Zhuang, Inner Mongolia, Ningxia Hui, Tibet and Xinjiang Uyghur) and four municipalities (Beijing, Chongqing, Shanghai and Tianjin). We divided the population into four mutually exclusive patient subgroups, based on their experience of COVID-19: (i) asymptomatic close contacts of suspected or confirmed cases of COVID-19, who were eventually diagnosed as COVID-19 negative; (ii) symptomatic suspected cases with or without close contact history with existing suspected or confirmed cases, who were eventually diagnosed as COVID-19 negative; (iii) confirmed cases of COVID-19, including those previously assessed as close contacts or suspected cases; and (iv) people not considered to have been exposed to COVID-19. We further divided confirmed cases into non-severe, severe and critical COVID-19, according to the disease severity (Box 1). Fig. 1 shows the diagnostic and treatment pathway for each patient subgroup; also described in the data repository. 9

Abstracts in العربية, 中文, Français, Русский and Español at the end of each article.
Outcomes

We estimated direct health-care costs, direct non-health-care cost and productivity losses for each region and for mainland China as a whole (Box 2). We calculated all costs in Chinese yuan (¥) at the 2019 value and converted to United States dollars (US$) using the annual exchange rate for 2019: US$ 1.00 = ¥ 6.91.9

Study period

Although COVID-19 was first identified in China in December 2019, 99.96% (74 648/74 675) of confirmed cases were identified in January and February 2020.10 From 6 March 2020, the number of new cases a day fell below 100, and no new cases were identified in 29 regions. Therefore, we calculated costs for the period from 1 January to 31 March 2020.

Cost estimation

There are two approaches to estimate the cost of illness: the bottom-up approach and the top-down approach.3 The bottom-up approach multiplies the average cost of the illness per patient by the prevalence of the illness. The top-down approach uses aggregated data and a population-attributable fraction to assign a percentage of total expenditure to the disease of interest. Because published total expenditure on COVID-19 was lacking (details in the data repository),3 we used the bottom-up approach. We estimated unit costs, $P_r$, at the patient or individual level for each component, $x$, of the overall burden of disease. We calculated the overall cost, $C$, as:

$$C = \sum x \times P_r \times i_x$$

where $i_x$ is the number of individuals affected.

Epidemiological data

Over the period of interest, the National Health Commission of the People’s Republic of China published national data on COVID-19 daily.11 However, detailed regional information was only published for Hubei province. Therefore, we manually extracted the number of newly identified close contacts, suspected cases and confirmed cases in each region from the daily updates reported by the local health commission of each region (details in the data repository).3 While all regions reported complete data for the number of confirmed cases and the numbers of deaths of confirmed cases, data were incomplete for the number of close contacts and/or suspected cases. We estimated these missing data either from published reports, or from the reported regional number of confirmed cases,13 assuming the same ratio between the number of close contacts or suspected cases and confirmed cases across regions.

Direct health-care cost

We used information in the published literature12,13 and clinical guidelines,2,3 supplemented with expert opinion where necessary, to estimate the health-care resources used for close contacts, suspected cases and confirmed cases. Shanghai is one of the few regions in China which reports full unit cost data.14 To calculate the unit costs for other regions, we calculated a health-care industry salary index (details in the data repository).9 We calculated a weight ($w_r$) for each region as:

$$w_r = \frac{s_r}{s}$$

where $s_r$ is the ratio of the average health-care industry salary in the region and $s$ is the average health-care industry salary in Shanghai.15 We then estimated regional unit costs ($P_r$) as:

$$P_r = P_s \times w_r$$

where $P_s$ is the unit costs derived from Shanghai.14

According to the State Council, 42 600 front-line health professionals worked with suspected and/or con-
Fig. 1. Simplified diagnostic and treatment pathway for COVID-19, China, 2020

COVID-19: coronavirus disease 2019.

Notes: The pathway is based on national and local clinical guidelines. Definitions of clinical symptoms and epidemiological history are in the data repository. Positive results for people monitored in hospital were positive nucleic acid test results and/or presence of lung imaging features consistent with coronavirus pneumonia.
confirmed COVID-19 cases. The daily risk subsidy for front-line health professionals was estimated to be ¥ 300.00 per person. We estimated the emergency funds (for construction of temporary emergency buildings and non-routine procurement of additional medical supplies and equipment) based on the budget plans of the Ministry of Finance and the National Development and Reform Commission (data repository). For reusable equipment, we only included the cost attributable to the 3-month period of the study in our analysis. Calculations and results for emergency funds are in the data repository.

Direct non-health-care cost

We estimated a daily cost of quarantine in Shanghai to be ¥ 75.00 (US$ 10.85), assuming that 50.0% of people quarantined at home at zero cost and 50.0% quarantined at a designated centre at the cost of ¥ 150.00 (US$ 21.71) a day. We calculated the regional quarantine costs per person (QCre) per person by category of exposure (e), as:

\[ Q_{C_re} = 75 w_r \times d_e \]  

where \( w_r \) is the regional weight described earlier and \( d_e \) is the estimated duration of quarantine.

The average cost of quarantine for close contacts and suspected cases was ¥ 1246.00 (US$ 180.32) and ¥ 735.00 (US$ 106.37) per person, respectively. We calculated the overall cost of quarantine (TQC) as:

\[ TQC = \sum_r \sum_e n_{re} \times w_r \times d_e \]  

where \( n_{re} \) is the number of people quarantined by region (r) and exposure (e) category. Details on methods and results are in the data repository.

Loss in productivity

We used the human capital approach to estimate productivity losses. For people not considered to have been exposed to COVID-19, we calculated costs by region (CP) as:

\[ CP_r = i_r \times f \times h_r \times q_r \]  

where \( i_r \) is the mean daily wage rate by region, \( f \) is the proportion of the population in employment, \( h_r \) is the mean number of days lost by region, and \( q_r \) is the regional population.

We obtained regional employment statistics from the China Statistical Yearbook 2019. The national average daily wage was ¥ 271.94 (US$ 39.35), ranging from ¥ 204.67 (US$ 29.62) in Heilongjiang province to ¥ 486.43 (US$ 70.40) in Beijing. The national unemployment rate was 3.0%, ranging from 1.4% in Beijing to 4.0% in Heilongjiang province. Data were not available on the employment status for close contacts, suspected cases and confirmed cases. Therefore, we estimated the employment rate, \( f \), for each patient subgroup at 54.0% based on the age and sex distribution of confirmed cases, the legal working age (16 years) and official retirement age (60 years for men and 50 years for women), and the national unemployment rate (3.0%). Employment rate calculations are in the data repository.

Sensitivity analysis

To determine which parameters were key cost drivers we conducted a sensitivity analysis. We identified costs that contributed to 10.0% or more of the total health-care costs and societal costs and varied the parameters for use of resources and unit cost. We used available data or our judgement to inform the ranges for the selected parameters.

Results

During the study period, there were 707 913 close contacts, 126 032 suspected cases and 81 879 confirmed cases in mainland China (Table 1). Of confirmed cases, 83.2% (68 127/81 879) were from Hubei province. Of close contacts and suspected cases, 5.2% (36 598/707 913) and 65.0% (81 879/126 032), respectively, were diagnosed with COVID-19. As regards severity, 81.5% (66 732/81 879) of the confirmed COVID-19 cases were non-severe, 13.8% (11 299/81 879) were severe and 4.7% (3848/81 879) were critical. Details by region are in the data repository.

Table 2 shows the health-care cost per person for each patient subgroup, based on the estimated use of resources and the unit costs from Shanghai. The health-care cost of managing close contacts and suspected cases diagnosed
as COVID-19 negative was ¥ 584.08 (US$ 84.53) and ¥ 973.70 (US$ 140.91) per person, respectively. The weighted average cost of treating a confirmed case of COVID-19 was ¥ 22,061.94 (US$ 3192.76), ranging from ¥ 6488.90 (US$ 939.06) for non-severe cases to ¥ 176,744.05 (US$ 25,578.01) for critical cases (data repository). We calculated costs of routine health-care services, quarantine and productivity losses, and total health-care and societal costs (Table 3). We estimated routine health-care costs at ¥ 2,151 (US$ 0.31) billion. Inpatient care accounted for 44.2% (¥ 0.95 billion/¥ 2.15 billion) of routine health-care costs, followed by medicines, which accounted for 32.5% (¥ 0.70 billion/¥ 2.15 billion), and medical observation of close contacts and suspected

| Region                                  | No. of close contacts | No. of suspected cases | No. of confirmed cases |
|-----------------------------------------|-----------------------|------------------------|------------------------|
|                                         | Total Diagnosis       | Total Diagnosis        | Total Survival outcome |
|                                         | Non-COVID-19          | COVID-19               | Non-COVID-19           | COVID-19 | Survived | Died |
| Anhui province                          | 28,981                | 27,445                 | 1,536                  | 1,129    | 139      | 990  |
| Beijing                                 | 4,164                 | 3,943                  | 221                    | 2,905    | 2,325    | 580  |
| Chongqing                               | 23,803                | 22,542                 | 1,261                  | 1,535    | 1,051    | 484  |
| Fujian province                         | 13,315                | 12,609                 | 706                    | 609      | 264      | 345  |
| Gansu province                          | 4,337                 | 4,107                  | 230                    | 691      | 553      | 138  |
| Guangdong province                      | 41,136                | 38,956                 | 2,180                  | 7,517    | 6,016    | 1,501 |
| Guangxi Zhuang autonomous region        | 16,216                | 15,357                 | 859                    | 816      | 562      | 254  |
| Guizhou province                        | 2,577                 | 2,508                  | 69                     | 736      | 589      | 147  |
| Hainan province                         | 6,574                 | 6,226                  | 348                    | 841      | 673      | 168  |
| Hebei province                          | 11,143                | 10,622                 | 521                    | 690      | 367      | 323  |
| Heilongjiang province                   | 16,619                | 16,491                 | 128                    | 1,535    | 1,051    | 484  |
| Henan province                          | 40,019                | 37,898                 | 2,121                  | 6,390    | 5,114    | 1,276 |
| Hubei province                          | 278,179               | 263,437                | 14,742                 | 68,127a  | 0        | 68,127a |
| Hunan province                          | 27,331                | 25,883                 | 1,448                  | 5,098    | 4,080    | 1,018 |
| Inner Mongolia autonomous region        | 3,123                 | 2,957                  | 166                    | 111a     | 0        | 111  |
| Jiangsu province                        | 12,843                | 12,162                 | 681                    | 3,335    | 2,589    | 646  |
| Jiangxi province                        | 27,310                | 25,863                 | 1,447                  | 4,693    | 3,756    | 937  |
| Jilin province                          | 3,994                 | 3,782                  | 212                    | 418      | 320      | 98   |
| Liaoning province                       | 3,729                 | 3,531                  | 198                    | 701      | 561      | 140  |
| Ningxia Hui autonomous region           | 4,719                 | 4,469                  | 250                    | 75a      | 0        | 75   |
| Qinghai province                        | 437                   | 414                    | 23                     | 18b      | 0        | 18   |
| Shandong province                       | 20,011                | 18,951                 | 1,060                  | 1,025    | 770      | 255  |
| Shanxi province                         | 20,733                | 19,634                 | 1,099                  | 3,876    | 3,102    | 774  |
| Shanghai                                | 14,142                | 13,393                 | 749                    | 2,584    | 2,068    | 516  |
| Sichuan province                        | 4,564                 | 4,350                  | 214                    | 301      | 164      | 137  |
| Tianjin                                 | 15,128                | 14,326                 | 802                    | 552a     | 0        | 552  |
| Tibet autonomous region                 | 3,994                 | 3,782                  | 212                    | 418      | 320      | 98   |
| Xinjiang Uighur autonomous region       | 3,008                 | 2,849                  | 159                    | 871      | 697      | 174  |
| Yunnan province                         | 10,899                | 10,321                 | 578                    | 911      | 729      | 182  |
| Zhejiang province                       | 46,764                | 44,286                 | 2,478                  | 6,295    | 5,038    | 1,257 |
| Total of all regions                    | 707,913               | 671,315                | 36,598                 | 126,032  | 44,153   | 81,879 |

Note: We obtained the data in regular font from the local health commission of each region. We calculated or estimated, or corrected the data in italic font.

COVID-19: coronavirus disease 2019; NR: not reported.

* The original number of suspected cases reported was lower than the number of confirmed cases. In such cases, the number of suspected cases was corrected to the number of confirmed cases (as a conservative proxy).

* Adjusted based on the corrected number reported by the Wuhan government on 17 April 2020.21

* Reported by the National Health Commission of the People's Republic of China.11
| Cost component                                      | Probability of using services | National unit cost, ¥ | Resource use | Cost per person, ¥ |
|----------------------------------------------------|-------------------------------|-----------------------|--------------|--------------------|
| **Close contact diagnosed as COVID-19 negative**    |                               |                       |              |                    |
| Case identification                                 | 1.00                          | 15.68 per case        | 1            | 15.68              |
| Nucleic acid test                                   | 1.00                          | 70.00 per test        | 2            | 140.00             |
| Medical observation                                 | 1.00                          | 35.00 per day         | 12.24        | 428.40             |
| **Total**                                           |                               |                       |              | 584.08 (US$ 84.53) |
| **Suspected case diagnosed as COVID-19 negative**   |                               |                       |              |                    |
| Outpatient consultation                             | 1.00                          | 12.60 per consultation| 1            | 12.60              |
| Nucleic acid test                                   | 1.00                          | 70.00 per test        | 2            | 140.00             |
| Other laboratory tests                              | 1.00                          | 282.10 per test       | 1            | 282.10             |
| Computed tomography scan                            | 1.00                          | 140.00 per scan       | 1            | 140.00             |
| Hospital bed days                                   | 1.00                          | 77.00 per day         | 2            | 154.00             |
| Medical observation                                 | 1.00                          | 35.00 per day         | 7            | 245.00             |
| **Total**                                           |                               |                       |              | 973.70 (US$ 140.91) |
| **Confirmed case, non-severe**                      |                               |                       |              |                    |
| Identification and diagnosis<sup>a</sup>            | 0.45                          | 636.30 per case       | 1            | 286.34             |
| Identification and diagnosis<sup>b</sup>            | 0.55                          | 549.92 per case       | 1            | 302.46             |
| Inpatient care<sup>c</sup>                          | 1.00                          | 389.40 per day        | 14           | 5451.64            |
| Medicines<sup>d</sup>                               | 1.00                          | 27.50 per day         | 14           | 385.04             |
| Treatment for pre-existing conditions               | 0.26                          | 10.50 per day         | 14           | 38.22              |
| Follow-up appointment                               | 1.00                          | 12.60 per appointment  | 2            | 25.20              |
| **Total**                                           |                               |                       |              | 6488.90 (US$ 939.06)|
| **Confirmed case, severe**                          |                               |                       |              |                    |
| Identification and diagnosis<sup>a</sup>            | 0.45                          | 636.30 per case       | 1            | 286.34             |
| Identification and diagnosis<sup>b</sup>            | 0.55                          | 549.92 per case       | 1            | 302.46             |
| Inpatient care<sup>c</sup>                          | 1.00                          | 592.79 per day        | 28           | 16 598.11          |
| Medicines<sup>d</sup>                               | 1.00                          | 1394.95 per day       | 28           | 39 058.64          |
| Treatment for pre-existing conditions               | 0.26                          | 645.25 per day        | 28           | 4697.44            |
| Oxygen therapy                                      | 1.00                          | 3.42 per hour         | 112          | 383.38             |
| Follow-up appointment                               | 1.00                          | 12.60 per appointment  | 2            | 25.20              |
| **Total**                                           |                               |                       |              | 61 351.57 (US$ 8 878.66)|
| **Confirmed case, critical**                        |                               |                       |              |                    |
| Identification and diagnosis<sup>a</sup>            | 0.45                          | 636.30 per case       | 1            | 286.34             |
| Identification and diagnosis<sup>b</sup>            | 0.55                          | 549.92 per case       | 1            | 302.46             |
| Inpatient care<sup>c</sup>                          | 1.00                          | 771.58 per day        | 42           | 32 406.43          |
| Medicines<sup>d</sup>                               | 1.00                          | 1 628.43 per day      | 42           | 68 394.24          |
| Treatment for pre-existing conditions               | 0.26                          | 481.03 per day        | 42           | 5 252.80           |
| Tracheostomy and tracheal intubation                | 1.00                          | 175.00 each           | 1            | 175.00             |
| Use of ventilator (including muscle relaxants)      | 0.71                          | Day 1: 1 892.38; Day 2 onwards: 1 402.38 | 30 | 30 218.58 |
| Extracorporeal membrane oxygenation                 | 0.12                          | Day 1: 42 000.00; Day 2 onwards: 7 000.00 | 20 | 21 000.00 |
| Artificial kidney                                  | 0.17                          | Day 1: 5 600.00; Day 2 onwards: 4 200.00 | 20 | 14 518.00 |
| Plasma exchange                                     | 0.17                          | 4 900.00 per exchange | 5            | 4 165.00           |
| Follow-up appointment                               | 1.00                          | 12.60 per appointment  | 2            | 25.20              |
| **Total**                                           |                               |                       |              | 176 744.05 (US$ 25 578.01)|

COVID-19: coronavirus disease 2019; ¥: Chinese yuan; US$: United States dollars.

<sup>a</sup> Identified from close contacts.
<sup>b</sup> Identified from suspected cases.
<sup>c</sup> Hospital bed days, nursing, blood gas analyses and laboratory tests.
<sup>d</sup> Anti-infective medicines and nutrition support.

Notes: Details for each individual cost component are in the data repository. For the confirmed cases, we assumed that 45% of them were identified from close contacts, whilst 55% were identified from suspected cases. Therefore, the cost of identification and diagnosis for all confirmed cases was calculated as the multiplication of the cost per case and 0.45 for close contacts and 0.55 for suspected cases.
cases, which accounted for 13.0% (¥ 0.28 billion/¥ 2.15 billion). Confirmed cases who died accounted for 32.4% (¥ 0.70 billion/¥ 2.15 billion) of routine health-care costs, severe cases who survived accounted for 27.8% (¥ 0.60 billion/¥ 2.15 billion), and non-severe confirmed cases who survived accounted for 17.4% (¥ 0.37 billion/¥ 2.15 billion). We estimated the cost of quarantine at ¥ 0.84 billion (US$ 0.12 billion), 96.0% (¥ 0.80 billion/¥ 2.15 billion) of which was spent on close contacts diagnosed as COVID-19 negative (Table 3). Our estimation of productivity losses was ¥ 2641.61 billion (US$ 383.02 billion; Table 3), which is equivalent to 2.7% of China's gross domestic product (GDP) in 2019 (US$ 14.14 trillion). Health-care costs accounted for only 0.2% (¥ 4.26 billion/¥ 2641.61 billion) of the societal cost while productivity losses accounted for 99.8% (¥ 2638.38 billion/¥ 2641.61 billion). Fig. 2 and Fig. 3 show the health-care cost and societal cost for each region, respectively. The health-care cost for Hubei province alone accounted for 66.7% (¥ 2.84 billion/¥ 4.26 billion) of the national health-care cost (Fig. 2). Guangdong province incurred the highest societal cost, followed by Jiangsu province and Beijing (Fig. 3).

The results of the sensitivity analyses are reported in the data repository. The direct health-care cost was most sensitive to the proportion of confirmed cases with severe or critical disease, and the health-care cost per person for treating severe and critical cases. The cost of the loss in productivity was most sensitive to the number of working days lost for people not considered to have had COVID-19, the national average daily salary, and assumptions on the effect of movement restriction policies on worker productivity.

**Discussion**

We estimated the health-care and societal costs associated with the COVID-19 outbreak in China for the first 3 months of 2020 to be ¥ 4.26 billion (US$ 0.62 billion) and ¥ 2646.70 billion (US$ 383.03 billion), respectively. Although the health-care cost per person for con-

---

**Table 3. Cost of COVID-19 according to cost component and COVID-19 diagnosis, China, January–March 2020**

| Cost component                      | Cost, million ¥ | Total cost, million ¥ | Total cost, million US$ |
|-----------------------------------|-----------------|------------------------|-------------------------|
| **Routine health care**           |                 |                        |                         |
| Identification and diagnosis      | N/A             | 95.16                  | 13.30                   | 33.91                   | 5.74                   | 0.27                   | 2.32                   | 150.70 (21.81)         |
| Medical observation<sup>a</sup>   | N/A             | 261.85                 | 17.50                   | N/A                     | N/A                     | N/A                     | 279.35 (40.43)         |
| Inpatient care                    | N/A             | 261.85                 | 17.50                   | N/A                     | N/A                     | N/A                     | 279.35 (40.43)         |
| Medicines                         | N/A             | 261.85                 | 17.50                   | N/A                     | N/A                     | N/A                     | 279.35 (40.43)         |
| Treatment for pre-existing conditions | N/A             | 261.85                 | 17.50                   | N/A                     | N/A                     | N/A                     | 279.35 (40.43)         |
| Follow-up for recovered cases     | N/A             | 803.17                 | 33.41                   | N/A                     | N/A                     | N/A                     | 836.58 (121.07)        |
| **Subtotal**                      | N/A             | 357.01                 | 44.26                   | 373.74                  | 598.19                  | 80.36                   | 969.03 (141.08)        |
| **Non-routine health care<sup>b</sup>** | N/A             | 803.17                 | 33.41                   | N/A                     | N/A                     | N/A                     | 836.58 (121.07)        |
| **Quarantine for test-negative cases** | N/A             | 2638.379.36            | 2635.33                 | 169.86                  | 328.63                  | 62.10                   | 265.71                 | 2641605.20 (382287.29) |
| Productivity loss                 | 2638.379.36     | 2635.33                | 169.86                  | 328.63                  | 62.10                   | 265.71                 | 2641605.20 (382287.29) |
| Total (societal cost)             | 2638.379.36     | 3795.51                | 247.53                  | 702.37                  | 660.29                  | 83.77                   | 722.54                 | 264698.18 (383024.34)<sup>c</sup> |

COVID-19: coronavirus disease 2019; N/A: not applicable; US$: United States dollars; ¥: Chinese yuan.

<sup>a</sup> Medical observation of close contacts and/or suspected cases before receiving a diagnosis of COVID-19.

<sup>b</sup> Includes risk subsidy for health-care staff and emergency funds for construction of temporary emergency buildings and non-routine procurement of additional medical supplies and equipment.

<sup>c</sup> Column total. We could not assign the cost of non-routine health care to any specific individual patient group so we only report the total cost of non-routine health care in the last column; therefore, the cost of non-routine health care is not reflected in the total societal cost for each patient subgroup (last row).
firmed cases was high. 99.9% of the societal cost was attributable to productivity losses in people not considered to have had COVID-19. These findings reflect the overall number of employed people in China (416.5 million), which is much larger than the number of confirmed cases (81,879 cases). Our estimated cost of productivity losses – ¥ 2641.61 billion (US$ 382.29 billion) – is comparable to the decrease in the Chinese GDP for the first quarter of 2020 compared with the same period in 2019: ¥ 1506.68 billion (US$ 218.04 billion).22

Hubei province, where most confirmed cases were identified, accounted for two thirds of the national health-care cost. The productivity loss was greatest for those regions with the highest number of employed people and/or the highest daily salary, such as Guangdong province (57.7 million employed people, ¥ 296.37, US$ 42.89, daily salary), Jiangsu province (42.2 million employed people, ¥ 279.41, US$ 40.44, daily salary) and Beijing (15.7 million employed people, ¥ 486.43, US$ 70.40, daily salary).

We did not identify any cost-of-illness studies for COVID-19 in our rapid review of the literature. Evidence on cost of illness is available for severe acute respiratory syndrome (SARS).23–27 To facilitate comparison of results, we inflated costs from the literature to 2019 values using a local consumer price index and converted to US$ using the annual exchange rate.28 Three studies23–25 reported the cost of managing patients with SARS; the health-care cost per case ranged from US$ 4151.00 in mainland China24 to US$ 362,700.00 in Canada.25
The cost for mainland China is similar to our estimate of US$ 3235 per COVID-19 case.\textsuperscript{24} An analysis of Chinese governmental health expenditure during 2002–2006 found that the SARS outbreak in 2003 increased governmental health expenditure by 4.1% (¥ 4.65 billion/¥ 113.39 billion).\textsuperscript{29} Another study used a simulation model to estimate the societal cost of SARS in 30 countries.\textsuperscript{30} The cost in mainland China was 1.03% (¥ 0.12 trillion/¥ 11.69 trillion) of GDP,\textsuperscript{30} which is comparable to our estimate of the societal cost of COVID-19 (2.7% of China’s GDP in 2019).\textsuperscript{22}

The societal cost of COVID-19 is substantial and greatly outweighs the health-care cost. Our analysis, which demonstrates the effect of COVID-19 beyond the health-care system, justifies the redirection of resources from other sectors of the economy to strengthen health systems, as the potential productivity losses caused by a pandemic may far exceed the health-care cost. Despite a lack of evidence on their cost–effectiveness, unprecedented controls on people’s movements and ability to work have been imposed in several countries in an attempt to reduce the spread of COVID-19. Future work will examine the cost–effectiveness of these policies. Our data can help inform these analyses by providing the cost of identifying, diagnosing and treating patients with suspected or confirmed COVID-19. Our analysis underlines the importance of action to strengthen health systems, particularly the capacity to test for infection and trace contacts, which has been identified as one of the most cost-effective policy responses.\textsuperscript{31} Effective disease mitigation action will require international cooperation and considerable investment. Underinvestment in strengthening the capacity of health systems to tackle future pandemics could prove to be far costlier than the additional investment required.

Our study has several strengths. This study fills an important evidence

\begin{figure}
\centering
\includegraphics[width=\textwidth]{societal_cost_map.png}
\caption{Societal cost of COVID-19 by region, China, January–March 2020}
\end{figure}

COVID-19: coronavirus disease 2019; ¥: yuan.
gap by presenting the first cost-of-illness study of COVID-19. The study identified the cost of the COVID-19 pandemic in different sectors of the economy; such data are necessary to inform planning of services and the prioritization of research. Our data also provide important information for future economic evaluations of interventions for COVID-19. We accessed detailed data on use of resources in the 31 regions of mainland China, including incidence of close contacts, suspected cases and confirmed cases, from the local health commission of each region. We applied unit cost data adjusted to reflect relative price differences across provinces, and used clinician input from Shanghai and Hubei province to check the use of resources for each subgroup (close contacts, suspected and confirmed cases). We estimated productivity costs for close contacts, suspected cases and confirmed cases based on the duration of quarantine and/or treatment, and regional migration patterns after the end of the extended Chinese New Year holiday period.

Our analysis also has some limitations. First, we only covered the first 3 months of the epidemic and therefore could not capture the long-term economic effects of COVID-19. Future research is needed to assess the long-term economic impact of COVID-19 on the health-care system (e.g. for management of chronic diseases) and on society (e.g. reduced international trade and increased unemployment rates). Second, due to a lack of data, we could not include some cost components, such as productivity losses for carers of suspected and confirmed cases and out-of-pocket payments for travel to hospitals and over-the-counter medicines. Third, because of a shortage of nucleic acid tests in China in January 2020, not all patients suspected of having COVID-19 were tested. Therefore, the reported number of confirmed cases is likely to be an underestimate, especially in Hubei province. Fourth, our estimate of the number of working days lost, which we based on migration data, may have overestimated losses for people who worked from home. Finally, we lacked some data on the incidence, demographic information and prognosis for close contacts and suspected cases, and had to estimate these data based on published literature and/or expert opinion. Finally, some positive effects of the restrictive measurements have been reported, such as reductions in crime rates,32 environmental improvements33 and a rapid increase in e-commerce.34 Analysis of the effects of these factors was beyond the scope of our study.

The results of our study highlight the substantial economic burden of the COVID-19 outbreak. Research is needed on the cost–effectiveness of different policies to control infectious diseases and developing capacity to limit the spread of disease while minimizing the impact on everyday life.

Acknowledgements
Huajie Jin and Haiyin Wang contributed equally to this work.

Funding: We received no funding for this research. HW received salary support from the Fourth Round of the Shanghai Three-year Action Plan on Public Health Discipline and Talent Program: Evidence-based Public Health and Health Economics (No. 15GWZK0901).

Competing interests: MP received personal fees from Merck and Initiate Consultancy, but not related to this work. All other authors declare no competing interests.
摘要

新冠肺炎于 2020 年 1 月至 3 月对中国造成的经济负担

目的 旨在估算新型冠状病毒肺炎（新冠肺炎）对中国 31 个省级行政区域造成的经济成本，包括卫生系统成本和社会成本。

方法 我们采用政府报告、临床指南和其他出版物中所汇报数据，估算了 2020 年 1 月 1 日至 3 月 31 日期间新冠肺炎的相关成本。成本构成包括：密切接触者的识别和诊断；新冠肺炎疑似病例和确诊病例的识别和诊断；新冠肺炎病例的治疗；密切接触者和疑似病例的强制隔离；以及所有受影响居民的生产力损失。

结果 新冠肺炎相关卫生和社会成本总额估算值分别为 42.6 亿元人民币（6.2 亿美元）和 26,467.0 亿元人民币（3,832.2 亿美元）。住院治疗费用占常规医疗费用的 44.2%（9.5 亿元人民币 / 21.5 亿元人民币），其次是药品费用，占 32.5%（7.0 亿元人民币 / 21.5 亿元人民币）。生产力损失占社会成本的 99.8%（26,416.1 亿元人民币 / 26,467.0 亿元人民币），这是由于行动限制政策对未感染新冠肺炎的人们造成影响所致。社会成本对因行动限制政策而损失的工资成本和工作天数最为敏感。湖北省的医疗成本最高，而广东省的社会成本最高。

结论 我们的研究结果表明，新冠肺炎疫情对中国造成了非常沉重的经济负担。为防止疾病传播而采取的控制措施导致生产力大幅损失，相当于中国年度国内生产总值的 2.7%（3,822.9 亿美元 / 14.14 万亿美元）。

Résumé

Fardeau économique de la COVID-19 en Chine entre janvier et mars 2020: étude sur le coût de la maladie

Objectif Estimer l'impact économique de la maladie à coronavirus 2019 (COVID-19) dans 31 régions administratives de niveau provincial ainsi que dans l'ensemble de la Chine.

Méthodes Nous avons utilisé les données issues des rapports officiels, des directives cliniques et d'autres publications pour évaluer les principales composantes de coût de la COVID-19 durant la période comprise entre le 1er janvier et le 31 mars 2020. Ces composantes étaient les suivantes: identification et diagnostic des contacts rapprochés; cas suspects et confirmés de COVID-19; traitement des cas de COVID-19; quarantaine obligatoire des contacts rapprochés et cas suspects; et enfin, perte de productivité pour toutes les personnes concernées. Le coût total des soins de santé et le coût total pour la société constituaient les résultats primaires.

Résultats Nous avons estimé que le coût total des soins de santé et le coût total pour la société induits par la COVID-19 s'élevaient à 4,26 milliards de yuans (0,62 milliard de dollars américains) dans le premier cas et à 26,467,0 milliards de yuans (383,02 milliards de dollars américains) dans le second. L'hospitalisation des patients a représenté 44,2% (0,95 milliard de yuans/2,15 milliards de yuans) des frais de soins de santé courants, suivie par les médicaments avec 32,5% (0,70 milliard de yuans/2,15 milliards de yuans). La perte de productivité a représenté 99,8% (26,416,1 milliards de yuans/26,467,0 milliards de yuans) du coût pour la société, principalement lié à l'impact des politiques de restriction des déplacements sur les personnes ne souffrant pas de la COVID-19. Le coût pour la société dépendait majoritairement des dépenses salariales et du nombre de jours de travail perdus à cause des politiques de restriction des déplacements. C'est la province du Hubei qui a déboursé le plus pour les soins de santé, tandis que celle du Guangdong a été la plus durement touchée en termes de coût pour la société.

Conclusion Nos résultats mettent en lumière le lourd fardeau économique de l'épidémie de COVID-19 en Chine. Les mesures de lutte contre la propagation du virus ont entraîné des pertes considérables en raison d'une baisse de productivité équivalant à 2,7% (382,29 milliards de dollars américains / 14,14 billions de dollars américains) du produit intérieur brut annuel de la Chine.

Резюме

Экономическое бремя COVID-19, Китай, январь-март 2020 г.: исследование для определения объема расходов, связанных с заболеванием

Цель Оценить экономический ущерб, нанесенный коронавирусной инфекцией (COVID-19) в 31 административном районе на уровне провинции и в целом по Китаю.

Методы Авторы использовали данные отчетов правительства, клинических рекомендаций и других публикаций для оценки основных компонентов затрат, связанных с COVID-19, в период с 1 января по 31 марта 2020 года. Этими компонентами были следующие: идентификация и диагностика лиц, находившихся в тесном контакте с заболевшими, подозрение на COVID-19 и подтвержденные случаи заболевания; лечение выявленных случаев заболевания COVID-19; обязательный карантин лиц, находившихся в тесном контакте с заболевшими, и случаев с подозрением на наличие инфекции; потеря работоспособности зараженной части населения. Показателями основных результатов были общие расходы на здравоохранение и социальные издержки.

Результаты Общие оценочные расходы на здравоохранение и социальные издержки, связанные с COVID-19, составили 4,26 трлн китайских юаней (0,62 трлн долларов США) и 26,467,0 трлн юаней (383,02 трлн долларов США) соответственно. На стационарное лечение приходилось 44,2% (0,95/2,15 трлн юаней) от планового уровня расходов на здравоохранение, далее следовали расходы на лекарственные препараты, составлявшие 32,5% (0,70/2,15 трлн юаней). На потерю работоспособности пришлось 99,8% (26,416,1 трлн юаней / 26,467,0 трлн юаней) социальных издержек, которые в основном были связаны с влиянием введенных ограничений на передвижения людей, которые не болели COVID-19. Издержки для общества были наиболее чувствительны к расходам на заработную плату и
Resumen

Carga económica de la COVID-19 en China entre los meses de enero-marzo de 2020: estudio del coste de la enfermedad

Objetivo
Estimar el coste económico de la enfermedad coronavirus-19 (COVID-19) en 31 regiones administrativas a nivel provincial y en su totalidad en China.

Métodos
Utilizamos los datos de los informes del gobierno, las guías clínicas y otras publicaciones para estimar los principales componentes del coste de la COVID-19 desde el 1 de enero al 31 de marzo de 2020. Estos componentes fueron: identificación y diagnóstico de contactos cercanos; casos sospechosos y casos confirmados de COVID-19; tratamiento de los casos de COVID-19; cuarentena obligatoria de contactos cercanos y casos sospechosos; y pérdidas de productividad para todos los residentes afectados. El principal resultado fue el coste total de la atención sanitaria y de la sociedad.

Resultados
El total estimado de los costes de atención sanitaria y de la sociedad asociados con la COVID-19 fue de 4.260 millones de yuanes chinos (¥; 0,62 mil millones de dólares estadounidenses) y 2.646,70 mil millones de yuanes (383,02 mil millones de dólares estadounidenses), respectivamente. La atención hospitalaria representó el 44,2% (0,95 mil millones/2,15 mil millones de yenes) de los costes de la atención sanitaria rutinaria, seguida de los medicamentos, que representaron el 32,5% (0,70 mil millones/2,15 mil millones de yenes). Las pérdidas de productividad representaron el 99,8% (2.641,61 mil millones/2.646,70 mil millones de yenes) de los costes de la sociedad, que se atribuyeron principalmente al efecto de las políticas de restricción de movimientos en las personas que no tenían COVID-19. Los costes sociales fueron más sensibles a los costes salariales y al número de días de trabajo perdidos debido a las políticas de restricción de movimiento. La provincia de Guangdong tenía el mayor coste de atención sanitaria, mientras que la provincia de Guangdong tenía el mayor coste social.

Conclusión
Nuestros resultados destacan la alta carga económica del brote de COVID-19 en China. Las medidas de control para evitar la propagación de la enfermedad dieron lugar a costes sustanciales por pérdidas de productividad que ascendieron al 2,7% (382,29 mil millones de dólares estadounidenses/14,14 millones de millones de dólares estadounidenses) del producto interno bruto anual de China.

Referencias

1. Weekly epidemiological and operational updates September 2020 – Coronavirus disease 2019 (COVID-19). Geneva. World Health Organization; 2020. Available from: https://www.who.int/docs/default-source/ coronavirus/situation-reports/20200926-weekly-epi-update.pdf?sfvrsn=9e354665_6 [cited 2020 Sep 9].
2. [Guidance on infection prevention and control for COVID-19]. Seventh edition. Beijing. The National Health Commission of the People’s Republic of China; 2020. Chinese. Available from: http://www.gov.cn/zhengce/zhengceku/2020-03/04/5486705/files/ae16049f304d7598711a0d4cbf874a3.pdf [cited 2020 Apr 9].
3. Handbook of COVID-19 prevention and treatment. Zhejiang: First Affiliated Hospital of Zhejiang University School of Medicine; 2020. Available from: https://esge.org/documents/Handbook_of_COVID-19_Prevention_and_Treatment.pdf [cited 2020 Apr 10].
4. Muhammad F. China combating COVID-19: lessons for unprepared South Asia. Shanghai. Fudan University; 2020. Available from: https://www.fudan.edu.cn/en/2020/0206/c1092a104273/page.htm [cited 2020 Apr 7].
5. Zhang J, Li X, Zhang Y, Deng X, Chen X, et al. Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study. Lancet Infect Dis. 2020 Jul;20(7):793–802. doi: http://dx.doi.org/10.1016/S1473-3099(20)30230-9 PMID: 32247532.
6. Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics. 2011 Aug;29(8):653–71. doi: http://dx.doi.org/10.2165/11588380-000000000-00000 PMID: 21604822.
7. [Clinical guideline for the identification and management of close contacts of COVID-19]. Beijing. Chinese Center for Disease Control and Prevention; 2020. Chinese. Available from: http://www.chinacdc.cn/jkzt/crb/zl/zkb_11803/jyk_118185/202002/W020200224476107086955.pdf [cited 2020 Apr 14].
Research

Cost of COVID-19, China

17. [Q & A of Ministry of Finance’s support on the prevention and treatment of COVID-19]. Beijing: Ministry of Finance of the People’s Republic of China; 2020. Chinese. Available from: http://www.mof.gov.cn/zhengwuxinxi/caizhengxinwen/202003/t20200320_3486097.htm [cited 2020 Apr 9].

18. [Baidu migration index – 24 March 2020] [Internet]. Beijing: Baidu; 2020. Chinese. Available from: https://mp.weixin.qq.com/s/zm4qME7XG5sWMcYufnpeXa [cited 2020 Apr 16].

19. Smith C. 90 amazing Baidu statistics and facts. By the numbers [Internet]. Boston: DMR; 2020. Available from: https://expandedramblings.com/index.php/baidu-stats/ [cited 2020 Apr 9].

20. [Human Resources and Social Affairs Bureau’s response to delay in work resumption]. Shanghai: The People’s Government of Shanghai; 2020. Chinese. Available from: http://www.shanghai.gov.cn/nw48607/20200826/0001-48607_63619.html [cited 2020 Nov 14].

21. Corrections of the COVID-19 statistics in Wuhan city 2020 [Internet]. Wuhan: Wuhan Municipal People’s Government; 2020. Available from: http://www.china.org.cn/china/Off_the_Wire/2020-04/17/content_75943843.htm [cited 2020 Nov 14].

22. [Gross domestic product in China, 2020] [Internet]. Beijing: National Bureau of Statistics of China; 2020. Chinese. Available from: http://www.stats.gov.cn/ [cited 2020 Apr 17].

23. Achonu C, Laporte A, Gardam MA. The financial impact of controlling a respiratory virus outbreak in a teaching hospital: lessons learned from SARS. Can J Public Health. 2005 Jan–Feb;96(1):52–4. doi: http://dx.doi.org/10.1007/BF03404018 PMID: 15682697

24. Xiao F, Chen BW, Wu YF, Wang YX, Han DM; Beijing (Provisional) Commanding Center For SARS Treatment and Cure Scientific Research Group. [Analysis on the cost and its related factors of clinically confirmed severe acute respiratory syndrome cases in Beijing]. Chinese. Zhonghua Liu Xing Bing Xue Za Zhi. 2004 Apr;25(4):312–6. PMID: 15231198

25. Yazdanpanah Y, Daval A, Alfandari S, Lenne X, Lavoine D, Verin I, et al. Analysis of costs attributable to an outbreak of severe acute respiratory syndrome at a French hospital. Infect Control Hosp Epidemiol. 2006 Nov;27(11):1282–5. doi: http://dx.doi.org/10.1086/508846 PMID: 17080396

26. Huang HH, Yen DH, Kao WF, Wang LM, Huang CJ, Lee CH. Declining emergency department visits and costs during the severe acute respiratory syndrome (SARS) outbreak. J Formos Med Assoc. 2006 Jan;105(1):31–7. doi: http://dx.doi.org/10.1016/S0929-6646(05)96010-6 PMID: 16440068

27. Chang HJ, Huang N, Lee CH, Hsu YJ, Hsieh CI, Chou YJ. The impact of the SARS epidemic on the utilization of medical services: SARS and the fear of SARS. Am J Public Health. 2004 Apr;94(4):562–4. doi: http://dx.doi.org/10.2105/AJPH.94.4.562 PMID: 15054005

28. Consumer price indices (CPIs) – complete database [Internet]. Paris: Organisation for Economic Co-operation and Development; 2020. Available from: https://stats.oecd.org/Index.aspx?DataSetCode=PRICES_CPI [cited 2020 Apr 8].

29. Pan J, Liu GG. The determinants of Chinese provincial government health expenditures: evidence from 2002–2006 data. Health Econ. 2012 Jul;21(7):757–77. doi: http://dx.doi.org/10.1002/hec.1742 PMID: 21560182

30. Lee J, McKibbin W. Learning from SARS. Preparing for the next disease outbreak. Washington, DC: National Academies Press; 2004. Available from: https://www.ncbi.nlm.nih.gov/books/NBK92473/ [cited 2020 Nov 13].

31. Juneau C-E, Pueyo T, Bell M, Gee G, Collazo P, Potvin L. Evidence-based, cost-effective interventions to suppress the COVID-19 pandemic: a systematic review (preprint). Cold Spring Harbor: medRxiv; 2020. doi: http://dx.doi.org/10.1101/2020.04.20.20054726d oi: http://dx.doi.org/10.1101/2020.04.20.20054726

32. Coronavirus and crime in England and Wales: August 2020 [Internet]. London: Office for National Statistics; 2020. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/crimeandjustice/bulletins/coronavirusandcrimeinenglandandwales/august2020#main-points [cited 2020 Oct 7].

33. Wang Q, Su M. A preliminary assessment of the impact of COVID-19 on environment – a case study of China. Sci Total Environ. 2020 Aug 1;728:138915. doi: http://dx.doi.org/10.1016/j.scitotenv.2020.138915 PMID: 32348946

34. Gao X, Shi X, Guo H, Liu Y. To buy or not buy food online: the impact of the COVID-19 epidemic on the adoption of e-commerce in China. PLoS One. 2020 Aug 20;15(8):e0237900. doi: http://dx.doi.org/10.1371/journal.pone.0237900 PMID: 32817693

124 Bull World Health Organ 2021;99:112–124 doi: http://dx.doi.org/10.2471/BLT.20.267112